image credit: Adobe Stock

New Competitor to Wegovy, Retatrutide, Shows Promise in Clinical Trials

June 27, 2023


An experimental drug appears to outperform the trendy medications Wegovy and Ozempic for both weight loss and diabetes control, a pair of early clinical trials shows.

Retatrutide helped people with obesity drop about one-quarter of their starting weight, on average, during 48 weeks taking the drug, according to phase 2 trial results published online June 26 in the New England Journal of Medicine.

“What is clear is that 24% weight loss from a single drug has not been seen before,” said co-researcher Dr. Lee Kaplan, an associate professor with Harvard Medical School. “And the subjects in the trial were still losing weight at the end.”